177 Plasma globotriaosylsphingosine and the natural Fabry disease course 25. Najafian, B.; Tondel, C.; Svarstad, E.; Gubler, M.C.; Oliveira, J.P.; Mauer, M., Accumulation of Globotriaosylceramide in Podocytes in Fabry Nephropathy Is Associated with Progressive Podocyte Loss. J Am Soc Nephrol, 2020. 31(4): p. 865-875. 26. van der Veen, S.J.; van Kuilenburg, A.B.P.; Hollak, C.E.M.; Kaijen, P.H.P.; Voorberg, J.; Langeveld, M., Antibodies against recombinant alpha-galactosidase A in Fabry disease: Subclass analysis and impact on response to treatment. Mol Genet Metab, 2019. 126(2): p. 162-168. 27. Alharbi, F.J.; Baig, S.; Auray-Blais, C.; Boutin, M.; Ward, D.G.; Wheeldon, N.; Steed, R.; Dawson, C.; Hughes, D.; Geberhiwot, T., Globotriaosylsphingosine (Lyso-Gb3) as a biomarker for cardiac variant (N215S) Fabry disease. J Inherit Metab Dis, 2018. 41(2): p. 239-247. 28. Niemann, M.; Rolfs, A.; Stork, S.; Bijnens, B.; Breunig, F.; Beer, M.; Ertl, G.; Wanner, C.; Weidemann, F., Gene mutations versus clinically relevant phenotypes: lyso-Gb3 defines Fabry disease. Circ Cardiovasc Genet, 2014. 7(1): p. 8-16. 29. Bouzas-Mosquera, A.; Broullon, F.J.; Alvarez-Garcia, N.; Peteiro, J.; Mosquera, V.X.; CastroBeiras, A., Association of left ventricular mass with all-cause mortality, myocardial infarction and stroke. PLoS One, 2012. 7(9): p. e45570. 30. Pieroni, M.; Moon, J.C.; Arbustini, E.; Barriales-Villa, R.; Camporeale, A.; Vujkovac, A.C.; Elliott, P.M.; Hagege, A.; Kuusisto, J.; Linhart, A.; et al., Cardiac Involvement in Fabry Disease: JACC Review Topic of the Week. J Am Coll Cardiol, 2021. 77(7): p. 922-936. 31. Sharp, A.S.; Tapp, R.J.; Thom, S.A.; Francis, D.P.; Hughes, A.D.; Stanton, A.V.; Zambanini, A.; O’Brien, E.; Chaturvedi, N.; Lyons, S.; et al., Tissue Doppler E/E’ ratio is a powerful predictor of primary cardiac events in a hypertensive population: an ASCOT substudy. Eur Heart J, 2010. 31(6): p. 747-752. 32. Saito, C.; Minami, Y.; Haruki, S.; Arai, K.; Ashihara, K.; Hagiwara, N., Prognostic Relevance of a Score for Identifying Diastolic Dysfunction according to the 2016 American Society of Echocardiography/European Association of Cardiovascular Imaging Recommendations in Patients with Hypertrophic Cardiomyopathy. J Am Soc Echocardiogr, 2021. 33. Ozbek, B.T.; Modin, D.; Mogelvang, R.; Jorgensen, P.G.; Jensen, M.T.; Schnohr, P.; Gislason, G.H.; Biering- Sorensen, T., Echocardiographic predictors of long-term adverse cardiovascular outcomes in participants with and without diabetes mellitus: A follow-up analysis of the Copenhagen City Heart Study. Diabet Med, 2021. 38(10): p. e14627. 34. Behera, M.K.; Swain, S.N.; Sahu, M.K.; Behera, G.K.; Mishra, D.; Narayan, J.; Singh, A.; Agarwal, S.; Mallick, P.K., Diastolic Dysfunction Is a Predictor of Poor Survival in Patients with Decompensated Cirrhosis. Int J Hepatol, 2021. 2021: p. 5592376. 35. Biegstraaten, M.; Arngrimsson, R.; Barbey, F.; Boks, L.; Cecchi, F.; Deegan, P.B.; FeldtRasmussen, U.; Geberhiwot, T.; Germain, D.P.; Hendriksz, C.; et al., Recommendations for initiation and cessation of enzyme replacement therapy in patients with Fabry disease: the European Fabry Working Group consensus document. Orphanet J Rare Dis, 2015. 10: p. 36. 5
RkJQdWJsaXNoZXIy MTk4NDMw